Follow up after curative-intent lung cancer treatment

Surveillance of lung cancer patients with integrated PET-CT or contrast-enhanced CT after curative-intent treatment: a prospective, randomized study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16281786

Enrollment

Registered

2017-02-23

Start date

2011-01-15

Completion date

Unknown

Last updated

2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer Cancer Non-small cell lung cancer

Interventions

Participants who have completed a curative-intent treatment are randomly allocated to one of two groups. Group 1 (Contrast-CT): Participants receive a CT scan every six months for two

Toshiba Medical Systems, Otawara, Japan). All chest MDCT examinations are obtained with the routine low dose chest MDCT protocol including craniocaudal direction, supine position with both arms rais

Bayer Vital Gmbh, Leverkusen, Germany) is tailored to the individual body weight: = 50kg = 80ml @ 2.5ml / second with a fixed contrast delay of 35 seconds. Radiation dose exposure is systematically re

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 18 years of age or older 2. Have a FDG-PET positive tumor 3. Completed a curative–intent treatment for NSCLC (the PET positivity and the curative character of the cancer therapy are board defined)

Exclusion criteria

Exclusion criteria: 1. Lack of written informed consent 2. Insufficient knowledge of the German language 3. Impaired kidney function (glomerular filtration rate lower than 30 ml/min).

Design outcomes

Primary

Measure	Time frame
Cancer recurrence or second primary cancer is assessed by further work up of a pathological finding in contrast-CT or PET-CT (the particular method of diagnostic work up is board-defined and does usually consist of either endoscopic or surgical biopsy) respectively and is performed at 6, 12,18 and 24 months.	—

Secondary

Measure	Time frame
1. Other pathological finding are measured through surveillance CT or PET-CT scans at 6,12,18, and 24 months 2. Symptomatic recurrences/patient pursuing medical help due to somatic symptoms is measured by methods that are chosen by the treating physician at any time when symptoms occur. Usually, these methods consist of computed tomography or magnet resonance imaging. The decision about the methods chosen in these situations is not part of the current study.	—

Measure

Time frame

1. Other pathological finding are measured through surveillance CT or PET-CT scans at 6,12,18, and 24 months 2. Symptomatic recurrences/patient pursuing medical help due to somatic symptoms is measured by methods that are chosen by the treating physician at any time when symptoms occur. Usually, these methods consist of computed tomography or magnet resonance imaging. The decision about the methods chosen in these situations is not part of the current study.

—

Countries

Switzerland

Contacts

Public ContactSarosh Irani

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 20, 2026